Comparative Pharmacology
Head-to-head clinical analysis: CRYSELLE versus CYCLAFEM 1 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRYSELLE versus CYCLAFEM 1 35.
CRYSELLE vs CYCLAFEM 1/35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cryselle is a combination oral contraceptive containing ethinyl estradiol and norgestrel. It inhibits ovulation by suppressing gonadotropin release, primarily through estrogenic and progestogenic effects on the hypothalamic-pituitary axis. It also increases cervical mucus viscosity and alters endometrial structure, impeding sperm penetration and implantation.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) secretion via estrogen and progestin negative feedback, inhibiting ovulation. Progestin alters cervical mucus (sperm penetration) and endometrial receptivity.
One tablet (0.3 mg norgestrel/0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo.
One tablet orally once daily. Each tablet contains 1 mg norethindrone and 0.035 mg ethinyl estradiol. Administer daily for 21 days followed by 7 days of placebo or no tablet.
None Documented
None Documented
Terminal elimination half-life approximately 24 hours (range 16-36 h), with clinical significance for once-daily dosing.
Half-life of norethindrone is 5-14 hours; ethinyl estradiol is 10-20 hours. Steady state reached after 5-7 days.
Renal (50% as metabolites, 20% unchanged), fecal (30%), with enterohepatic recirculation.
Renal 40-60% as glucuronide and sulfate conjugates, biliary/fecal 20-40%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive